Trial reportClinical pharmacology in drug development2026
Comparative Bioavailability of a Fixed-Dose Combination of Etoricoxib and Betamethasone in Healthy Volunteers.
Trial report in Clinical pharmacology in drug development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study evaluated the pharmacokinetic profiles and comparative bioavailability of etoricoxib 90 mg tablets and betamethasone 0.25 mg/0.5 mL solution, administered individually (reference drugs), versus a fixed-dose combination (FDC) tablet containing etoricoxib 90 mg and betamethasone 0.25 mg (test drug) under fasting conditions in healthy Mexican volunteers. A randomized, open-label, three-period, crossover, single-dose study with a 14-day washout period was conducted. Study drugs were administered orally following a 10-h overnight fast with 250 mL of water and fasting continued for at least 4 h post-dose. Serial blood samples were collected pre- and post-dose, and the drug concentrations were quantified using Liquid Chromatography coupled to Tandem Mass Spectrometry (LC-MS/MS). Forty-two subjects (22 women, 20 men; mean age 22.7 years; mean weight 64.7 kg) were enrolled, and 39 completed the study. Comparative bioavailability was established if the 90% confidence intervals of log-transformed C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.